The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Immune checkpoint inhibitor-induced colitis: A comprehensive review
Open accessAbstract
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target down-regulators of the anti-cancer immune response: Cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand programmed death-ligand 1. ICIs have revolutionized the treatment of a variety of malignancies. However, many immune-related adverse events have also been described which mainly occurs as the immune system becomes less suppressed, affecting various organs including the gastrointestinal tract and causing diarrhea and colitis. The incidence of immune-mediated colitis (IMC) ranges from 1%-25% depending on the type of ICI and if used in combination. Endoscopically and histologically there is a significant overlap between IMC and inflammatory bowel disease, however more neutrophilic inflammation without chronic inflammation is usually present in IMC. Corticosteroids are recommended for grade 2 or more severe colitis while holding the immunotherapy. About one third to two thirds of patients are steroid refractory and benefit from infliximab. Recently vedolizumab has been found to be efficacious in steroid and infliximab refractory cases. While in grade 4 colitis, the immunotherapy is permanently discontinued, the decision is controversial in grade 3 colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 627
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 559
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.
Allison, J. P., McIntyre, B. W., & Bloch, D. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.5.2293 · Cited by 541
Treg and CTLA-4: Two intertwining pathways to immune tolerance
Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 411
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00005 · Cited by 377
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., Bourdier de Beauregard, M., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv227 · Cited by 340
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., Arancia, G., Anichini, A., Fais, S., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18809.x · Cited by 289
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., & Weber, J. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277
Geukes Foppen, M. H., Rozeman, E. A., van Wilpe, S., Postma, C., Snaebjornsson, P., van Thienen, J. V., van Leerdam, M. E., van den Heuvel, M., Blank, C. U., van Dieren, J., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000278 · Cited by 274
Systematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J. S., Galbraith, S. M., Targan, S. R., & Wang, H. L. (2010) · PubMed · Cited by 258
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez-Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 250
Wang, Y., Abu-Sbeih, H., Mao, E., Ali, N., Ali, F. S., Qiao, W., Lum, P., Raju, G., Shuttlesworth, G., Stroehlein, J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0346-6 · Cited by 243
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Wang, Y., Abu-Sbeih, H., Mao, E., Ali, N., Qiao, W., Trinh, V. A., Zobniw, C., Johnson, D. H., Samdani, R., Lum, P., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy104 · Cited by 240
Tarhini, A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 236
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Abu-Sbeih, H., Ali, F. S., Alsaadi, D., Jennings, J., Luo, W., Gong, Z., Richards, D. M., Charabaty, A., & Wang, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0461-4 · Cited by 215
Self-citationNatural T cell immunity against cancer.
Nagorsen, D., Scheibenbogen, C., Marincola, F. M., Letsch, A., & Keilholz, U. (2003) · PubMed · Cited by 196
Introduction to checkpoint inhibitors and cancer immunotherapy
Sharpe, A. H. (2017) · Immunological Reviews · doi:10.1111/imr.12531 · Cited by 177
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw141 · Cited by 177
Kaehler, K. C., Piel, S., Livingstone, E., Schilling, B., Hauschild, A., & Schadendorf, D. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.003 · Cited by 170
Coutzac, C., Adam, J., Soularue, É., Collins, M., Racine, A., Mussini, C., Boselli, L., Kamsu-Kom, N., Mateus, C., Charrier, M., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx081 · Cited by 169
Shelton, E., Laharie, D., Scott, F. I., Mamtani, R., Lewis, J. D., Colombel, J., & Ananthakrishnan, A. N. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.037 · Cited by 165
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 164
α-CTLA-4 mAb-associated Panenteritis: A Histologic and Immunohistochemical Analysis
Oble, D. A., Mino-Kenudson, M. A., Goldsmith, J. D., Hodi, F. S., Seliem, R. M., Dranoff, G., Mihm, M. C., Hasserjian, R. P., & Lauwers, G. Y. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817150e3 · Cited by 152
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 150
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 147
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Verschuren, E. C., van den Eertwegh, A. J. M., Wonders, J., Slangen, R. M. E., van Delft, F., Bodegraven, A. A. V., Neefjes‐Borst, A., & de Boer, N. K. H. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.028 · Cited by 147
Fehleisen, N. (1882) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0029-1196806 · Cited by 141
Bowyer, S. E., Prithviraj, P., Lorigan, P. C., Larkin, J., McArthur, G. A., Atkinson, V. G., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.107 · Cited by 139
Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2505 · Cited by 129
Emerging role of calprotectin in gastroenterology
Poullis, A. P., FOSTER, R., Mendall, M. A., & Fagerhol, M. K. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03014.x · Cited by 126
Toxicity management of immunotherapy for patients with metastatic melanoma
Linardou, H., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.10 · Cited by 114
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Scarpati, G. D. V., Fusciello, C., Perri, F., Sabbatino, F., Carlomagno, C., Pepe, S., & Ferrone, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s57335 · Cited by 106
Lankes, K., Hundorfean, G., Harrer, T., Pommer, A. J., Agaimy, A., Angelovska, I., Tajmir-Riahi, A., Göhl, J., Schuler, G., Neurath, M. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1128611 · Cited by 88
Jain, A., Lipson, E. J., Sharfman, W. H., Brant, S. R., & Lazarev, M. G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i11.2023 · Cited by 85
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Prieux‐Klotz, C., Dior, M., Damotte, D., Dréanic, J., Brieau, B., Brézault, C., Abitbol, V., Chaussade, S., & Coriat, R. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0495-4 · Cited by 78
Schindler, K., Harmankaya, K., Kuk, D., Mangana, J., Michielin, O. A., Höeller, C., Dummer, R., Pehamberger, H., Wolchok, J. D., & Postow, M. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9096 · Cited by 71
Vedolizumab: a novel treatment for ipilimumab-induced colitis
Hsieh, A. H., Ferman, M., Brown, M. P., & Andrews, J. M. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216641 · Cited by 60
Nagai, H., & Muto, M. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1259-6 · Cited by 60
Smith, F. O., Goff, S. L., Klapper, J. A., Levy, C. L., Allen, T., Mavroukakis, S. A., & Rosenberg, S. A. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211334.06762.89 · Cited by 51
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00311 · Cited by 48
Cohn, H. M., Dave, M., & Loftus, E. V. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001199 · Cited by 47
Dadheech, N., Srivastava, A., Paranjape, N., Gupta, S., Dave, A., Shah, G. M., Bhonde, R. R., & Gupta, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128244 · Cited by 36
Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
Bourke, J., O'Sullivan, M. D., & Khattak, M. A. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00586 · Cited by 35
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis
Diana, P., Mankongpaisarnrung, C., Atkins, M. B., Zeck, J. C., & Charabaty, A. (2018) · ACG Case Reports Journal · doi:10.14309/crj.2018.17 · Cited by 35
Self-citationDilling, P., Walczak, J., Pikiel, P., & Kruszewski, W. J. (2014) · Polish Journal of Surgery · doi:10.2478/pjs-2014-0017 · Cited by 33
Ipilimumab-induced colonic perforation
Burdine, L. J., Lai, K., & Laryea, J. A. (2014) · Journal of Surgical Case Reports · doi:10.1093/jscr/rju010 · Cited by 29
Infectious Colitis Associated With Ipilimumab Therapy
McCutcheon (2014) · Gastroenterology Research · doi:10.14740/gr594e · Cited by 25
Guthery, S. L., Heubi, J. E., & Filipovich, A. H. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704474 · Cited by 19
Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease
Chascsa, D. M. H., & Rakela, J. L. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0408-8 · Cited by 12
Cited by
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 380
Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J., & Manne, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.779691 · Cited by 344
Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0637 · Cited by 41
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Metadata
- Authors
- Som, A., Mandaliya, R., Alsaadi, D., Farshidpour, M., Charabaty, A., Malhotra, N., & Mattar, M. C.
- Venue
- World Journal of Clinical Cases
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2019-02-26
- Volume
- 7
- Issue
- 4
- Pages
- 405-418
- ISSN
- 2307-8960 (ISSN-L)
- OpenAlex
- W2917155973
- Cited by
- 265
- References
- 81
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.